IMPACT Therapeutics, Inc. (IMPACT) is a China-based clinical-stage company, dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. Funded by renowned venture capitals and operated by seasoned management team, IMPACT is developing innovative anti-cancer drugs with its unique new drug research and development methods, focusing on novel MOA especially synthetic lethality.
IMPACT has made tremendous progress in several drug discovery projects, including PARP inhibitor, hedgehog inhibitor and novel DDR agents. IMPACT holds global intellectual property rights of all its projects. The most advanced program is PARP inhibitor IMP4297, which is not only much more potent but also more selective than other PARP inhibitors in preclinical studies. IMP4297 is completing Phase I studies in Australia & China. Early clinical readouts suggest that IMP4297 is a potential best-in-class PARP inhibitor which could be highly efficacious and well tolerated in patients. IMPACT also is developing hedgehog pathway inhibitor IMP5471 as potential treatment for cancers and fibrosis diseases, as well as other DDR agents for the treatment of cancer.